PMID- 21447089
OWN - NLM
STAT- MEDLINE
DCOM- 20110621
LR  - 20220408
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 86
IP  - 5
DP  - 2011 May
TI  - Identification of the STAT5B-RARalpha fusion transcript in an acute promyelocytic 
      leukemia patient without FLT3, NPM1, c-Kit and C/EBPalpha mutation.
PG  - 442-6
LID - 10.1111/j.1600-0609.2011.01595.x [doi]
AB  - T(15;17) is the most common chromosomal aberration in patients with acute 
      promyelocytic leukemia (APL), leading to the formation of PML-RARalpha fusion gene. 
      In a small subset of patients with APL, the RARalpha gene is fused with different 
      partners. Here, we report a rare APL case with STAT5B-RARalpha fusion transcript. 
      Cytomorphologic and immunophenotypic analyses showed typical features of APL. 
      However, cytogenetic analysis showed normal karyotype, and interphase 
      fluorescence in situ hybridization (FISH) showed PML-RARalpha negative. Quantitative 
      RT-PCR also showed PML-RARalpha negative but STAT5B-RARalpha positive and sequencing 
      analysis confirmed the result. Molecular markers including FLT3, NPM1, c-Kit and 
      C/EBPalpha mutation were all negative. To our knowledge, this is the first APL 
      patient with STAT5B-RARalpha in Chinese population and the fifth patient around the 
      world according to published paper.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Qiao, Chun
AU  - Qiao C
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing, China.
FAU - Zhang, Su-Jiang
AU  - Zhang SJ
FAU - Chen, Li-Juan
AU  - Chen LJ
FAU - Miao, Kou-Rong
AU  - Miao KR
FAU - Zhang, Jian-Fu
AU  - Zhang JF
FAU - Wu, Yu-Jie
AU  - Wu YJ
FAU - Qiu, Hai-Rong
AU  - Qiu HR
FAU - Li, Jian-Yong
AU  - Li JY
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110330
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (CCAAT-Enhancer-Binding Protein-alpha)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (NPM1 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (STAT5 Transcription Factor)
RN  - 0 (STAT5-RARalpha protein, human)
RN  - 117896-08-9 (Nucleophosmin)
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Base Sequence
MH  - CCAAT-Enhancer-Binding Protein-alpha/genetics
MH  - DNA Mutational Analysis
MH  - DNA, Neoplasm/genetics
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Promyelocytic, Acute/*genetics/therapy
MH  - Male
MH  - Mutation
MH  - Nuclear Proteins/genetics
MH  - Nucleophosmin
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Proto-Oncogene Proteins c-kit/genetics
MH  - STAT5 Transcription Factor/*genetics
MH  - fms-Like Tyrosine Kinase 3/genetics
EDAT- 2011/03/31 06:00
MHDA- 2011/06/22 06:00
CRDT- 2011/03/31 06:00
PHST- 2011/03/31 06:00 [entrez]
PHST- 2011/03/31 06:00 [pubmed]
PHST- 2011/06/22 06:00 [medline]
AID - 10.1111/j.1600-0609.2011.01595.x [doi]
PST - ppublish
SO  - Eur J Haematol. 2011 May;86(5):442-6. doi: 10.1111/j.1600-0609.2011.01595.x. Epub 
      2011 Mar 30.